Doron Therapeutics November 2024 Series A Funding Round

Doron Therapeutics has successfully secured $11 million in a Series A funding round, led by SPRIM Global Investments, to advance its regenerative biologic drug, MOTYS™, into Phase 3 clinical trials for knee osteoarthritis. MOTYS™ is an intra-articular therapy designed to reduce pain and restore function with durable effects, backed by promising clinical and preclinical data. The funding will also support the expansion of Doron's board with experienced professionals, emphasizing the company’s goal to address the unmet need for non-surgical osteoarthritis treatments.